

the Department of Consumer and Corporate Affairs (CCA) shows that these promised benefits failed to materialize. Amongst its findings:

- Bill C-22 created less than half of the promised 3,000 jobs, mostly in marketing with only one-third of the jobs in R & D.
- Most of the R & D undertaken by the drug companies in Canada involves the testing of new products developed elsewhere, with very little in basic research.
- Canadian drug manufacturing remains a mixing and repackaging operation, with no ability to produce active ingredients (these are imported from elsewhere).

These findings, based on the experience under Bill C-22 since 1987, show that the industrial policy benefits failed to materialize. Unfortunately, the critics of Bill C-22 have been proven right! We have rapidly escalating drug prices as a result of extending monopoly protection up to 7-10 years, no side benefits in terms of jobs, R & D, etc. Why are we proposing to double this monopoly protection under Bill C-91?